Betreuungsdimensionen und Verläufe

Zusammenfassung

Chronische Erkrankungen bieten Versorgungsprobleme in drei Dimensionen: Manifeste Symptomatik - Risikofaktor - Behinderung. Diese erfordern jeweils ganz spezifische Behandlungsstrategien. Je nach Erkrankung, Krankheitsphase und persönlichen Umständen können sie rasch wechseln und/oder in Kombination auftreten. Die einzigartige Position des Hausarztes erlaubt und erfordert es, diese drei Dimensionen zu integrieren. Dabei werden übergreifend auch die Komponenten der Komorbidität (Anamnese des Patienten), der familiären, beruflichen und weiteren sozialen Situation, sowie seine Krankheits-Vorstellungen und Überzeugungen mitberücksichtigt.

Abstract

We postulate three dimensions of care for the chronically ill. Providers are expected to treat acute and chronic symptoms, to modify risk states and to provide rehabilitation for long-term disability. Dimensions of care change with disease diagnosis/progression and depending on the psychosocial situation of the individual patient. Primary care practitioners are in a unique position to improve well-being and prognosis in all three dimensions. Comorbidity, family, job-situation and wider community, subjective explanatory models and health beliefs are also important.

Schlüsselwörter

Chronische Krankheit - Hausarzt - medizinische Grundversorgung - Behandlungserfolg (MeSH)

Key words

Chronic Disease - Family Practice - Primary Health Care - Treatment Outcome (MeSH)

Literatur

• 1 Murray SA, Kendall M, Boyd K, Sheikh A. Illness trajectories and palliative care.  BMJ. 2005;  330 1007-1011
• 2 Gergen MM. Narrative structures in social explanation. In: Antaki C Analysing everyday explanation. London: Sage 1988
• 3 Lindahl B, Sandman PO, Rasmussen BH. On being dependent on home mechanical ventilation: Depictions of patients’ experiences over time.  Qualitative Health Research. 2006;  16 881-901
• 4 Gruenberg EM. The failures of success.  MMFQ. 1977;  , Winter 3-24
• 5 Fries JF. Aging, natural death, and the compression of morbidity.  N Engl J Med. 1980;  303 130-135
• 6 Vita AJ, Terry RB, Hubert HB, Fries JF. Aging, health risks, and cumulative disability.  N Engl J Med. 1998;  338 1035-1041
• 7 Schneider EL, Brody JA. Aging, natural dealth, and the compression of morbidity: another view.  N Engl J Med. 1983;  309 854-855
• 8 Oeppen J, Vaupel JW. Broken lilmits to live expectancy.  Science. 2002;  296 1029-1030
• 9 Barer ML, Evans RG, Hertzman C, Lomas J. Anging and health care utilization. New evidence on old fallacies.  Soc Sci Med. 1987;  24 851-862
• 10 Manton K. Changing concepts of morbidity and mortality in the elderly population.  MMFQ/Health and Society. 1982;  60 183-244
• 11 Katz S, Branch LG, Bransson MH, Papsidero JA, Beck JC, Greer DS. Active life expectancy.  N Engl J Med. 1983;  309 1218-1224
• 12 Antithrombotic Trialists' Collaboration . Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.  BMJ. 2002;  324 71-86
• 13 Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C. et al . Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.  Lancet. 2005;  366 1267-1278
• 14 Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease. A systematic review.  JAMA. 2003;  290 86-97
• 15 Bucher HC, Hengstler P, Schindler C, Guyatt GH. Percutaneous transluminal coronary angioplasty versus medical treatment for non-acute coronarary heart disease: meta-analysis of randomised controlled trials.  BMJ. 2000;  321 73-77
• 16 Nordmann AJ, Hengstler P, Leinenstoll BM, Harr T, Young J, Bucher HC. Clinical outcomes of stents versus balloon angioplasty in non-acute coronary artery disease. An meta-analysis of randomized controlled trials.  Eur Heart J. 2004;  25 69-80

Korrespondenzadresse